- Home
- YI vs CTSO Comparison
YI vs CTSO Comparison
Compare YI & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- CTSO
- Stock Information
- Founded
- YI 2010
- CTSO 1997
- Country
- YI China
- CTSO United States
- Employees
- YI N/A
- CTSO N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- CTSO Medical/Dental Instruments
- Sector
- YI Consumer Staples
- CTSO Health Care
- Exchange
- YI Nasdaq
- CTSO Nasdaq
- Market Cap
- YI 56.5M
- CTSO 68.2M
- IPO Year
- YI N/A
- CTSO N/A
- Fundamental
- Price
- YI $8.00
- CTSO $0.88
- Analyst Decision
- YI
- CTSO Strong Buy
- Analyst Count
- YI 0
- CTSO 3
- Target Price
- YI N/A
- CTSO $4.67
- AVG Volume (30 Days)
- YI 10.7K
- CTSO 138.7K
- Earning Date
- YI 05-22-2025
- CTSO 05-14-2025
- Dividend Yield
- YI N/A
- CTSO N/A
- EPS Growth
- YI N/A
- CTSO N/A
- EPS
- YI N/A
- CTSO N/A
- Revenue
- YI $1,973,017,082.00
- CTSO $35,594,520.00
- Revenue This Year
- YI N/A
- CTSO $18.72
- Revenue Next Year
- YI N/A
- CTSO $19.75
- P/E Ratio
- YI N/A
- CTSO N/A
- Revenue Growth
- YI N/A
- CTSO 14.51
- 52 Week Low
- YI $0.41
- CTSO $0.70
- 52 Week High
- YI $11.35
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- YI 49.29
- CTSO 37.43
- Support Level
- YI $7.48
- CTSO $0.87
- Resistance Level
- YI $8.40
- CTSO $1.16
- Average True Range (ATR)
- YI 0.36
- CTSO 0.06
- MACD
- YI -0.02
- CTSO -0.02
- Stochastic Oscillator
- YI 40.16
- CTSO 7.79
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.